Introduction {#s1}
============

The influenza pandemic in 2009 had a strong effect on clinical practice, and pneumonia is the leading complication of influenza virus infection \[[@R1]\]. Globally, influenza causes significant morbidity and mortality that respectively result in severe illness in 3 to 5 million people and death in up to 500,000 during epidemic years \[[@R2]\]. Of the complications of influenza, pneumonia is the most serious. The excess morbidity and mortality associated with influenza epidemics are generally reflected by high rates of pneumonia and hospitalization associated with influenza. Influenza-associated pneumonia (*flu-p*) is an independent factor of mortality \[[@R3]\]; however, there are few reports on the clinical features, treatment, and factors contributing to the severity and mortality of *flu-p*\[[@R4]\]. Increased understanding of these factors is expected to lead to appropriate prevention and management of *flu-p* and mitigate negative outcomes. Therefore, the purpose of this study was to investigate the clinical features and factors contributing to the severity and mortality of *flu-p*.

Patients and Methods {#s2}
====================

We conducted a retrospective study of consecutive patients hospitalized with *flu-p* from December 1999 through March 2016 at our institution in Saitama, Japan. The performance status (PS) \[[@R5]\] of the patients' in performing daily life activities before the development of pneumonia was recorded on admission based on anamnesis from the patients and their families. Excluded patients comprised those showing immunosuppression (AIDS or receiving chemotherapy) and those with tuberculosis, non-resected lung cancer, or confirmed alternative diagnosis lasting until the end of the follow-up period.

Healthcare-associated pneumonia (HCAP) was defined according to the criteria of the American Thoracic Society/Infectious Disease Society of America (ATS/IDSA) guidelines \[[@R6]\]. Diagnosis of causative microorganisms was based on results of semi-quantitative culture of respiratory samples or blood, paired sera, urinary antigen tests for *Streptococcus pneumoniae* and *Legionella pneumophila*, and reverse transcription polymerase chain reaction (RT-PCR), as reported previously \[[@R7],[@R8]\]. The types of *flu-p* were judged by respiratory physicians based on a previous report \[[@R9]\]. Patients with *flu-p* with an incomplete work-up of mixed infection or anamnesis were classified as having an "unclassified" pneumonia subtype. Severe pneumonia was defined when at least one major criterion or three minor criteria of the IDSA/ATS guidelines \[[@R10]\] were present. Complications were counted as described in a previous report \[[@R11]\]. The definition of acute kidney injury can be found elsewhere \[[@R12]\]. Approval for this study was obtained from the institutional clinical research ethics board of Saitama Cardiovascular and Respiratory Center (no. 2016003).

Statistical Analysis {#s2a}
--------------------

Data are presented using descriptive statistics for continuous variables and frequencies for categorical variables. Differences between groups were analyzed with analysis of variance (ANOVA) for continuous variables and chi-square tests for categorical variables. Risk factors for severe pneumonia and mortality were evaluated by univariate and multivariate logistic regression analyses. Variables that were considered to be relevant or found to be significant by the univariate analysis were included in the multivariate logistic regression analysis. With respect to the events of mortality, Firth's bias correction was used to alleviate the small number of the events in the logistic analyses \[[@R13]\]. A two-sided *P* value \< 0.05 was considered statistically significant in all tests. All statistical analyses were performed with SAS version 9.4 (SAS Institute, Inc., Cary, NC).

Results {#s3}
=======

Patients {#s3a}
--------

From December 1999 to March 2016, 210 patients ≥ 18 years old with *flu-p* were admitted to our institution. The median patient age was 69 (range, 17 to 92) years, and 151 (71.9 percent) were men ([Table 1](#T1){ref-type="table"}). One hundred thirty-three patients had a smoking history, and 12 had received long-term oxygen therapy. Charlson's comorbidity index was low in 87, medium in 115, high in 7, and very high in 1 patient. Body mass index was ≥ 25 kg/m^2^ in 22 patients and \< 18 kg/m^2^ in 33. Patients' PS as classified by the Eastern Cooperative Oncology Group \[[@R5]\] included PS 0 in 102, PS 1-2 in 42, PS 3-4 in 40, and unknown in 46 patients. Only 7 patients received 23-valent pneumococcal vaccine, and 31 patients received influenza vaccine. Of the 24 patients who were treated with neuraminidase inhibitors (NI) before presenting to our hospital, half had received NI within 48 hours after onset of initial symptoms. The pneumonia subtypes included primary viral pneumonia (*n* = 76, 36.2 percent), mixed viral and bacterial pneumonia (*n* = 71, 33.8 percent), secondary bacterial pneumonia (*n* = 34, 16.2 percent), and unclassified pneumonia (*n* = 29, 13.8 percent). The reason for the pneumonia subtype being "unclassified" was an incomplete work-up of mixed infection in 6 patients and incomplete anamnesis in 23 patients. None of the female patients were pregnant. Among the four *flu-p* subtypes, the ratio of men, vaccination history of influenza vaccine within one year, and incidences of chronic obstructive pulmonary disease (COPD), bronchiectasis, and premorbid PS differed significantly ([Table 1](#T1){ref-type="table"}).

Viral Subtypes {#s3b}
--------------

Diagnosis of viral subtypes was based on an influenza rapid diagnostic test in 154 patients, increased antibody titers in 82 patients, and positive RT-PCR in 12 patients ([Table 2](#T2){ref-type="table"}). The viral subtypes included pH1N1 (*n* = 23, 11.0 percent), H3N2 (*n* = 48, 22.9 percent), seasonal H1N1 (sH1N1) (*n* = 8, 3.8 percent), B (*n* = 46, 21.9 percent), and A but with subtypes not differentiated (*n* = 85, 40.5 percent).

Etiology of Mixed Infection {#s3c}
---------------------------

Methods used to identify the etiology of pneumonia are shown in [Table 2](#T2){ref-type="table"}. The most common microorganism in mixed infection was *S. pneumoniae*, and other microorganisms included *Haemophilus influenzae*, *Mycoplasma pneumoniae*, *Chlamydophila pneumoniae*, and others. Etiologies of mixed or secondary infection both in patients with severe disease and in non-survivors are listed in [Table 3](#T3){ref-type="table"}.

Complications of *flu-p* on Admission {#s3d}
-------------------------------------

The patients had several complications on admission: pneumothorax (*n* = 4, 1.9 percent), pyothorax (*n* = 2, 1.0 percent), acute kidney injury (*n* = 7, 3.3 percent), acute pulmonary thromboembolism (*n* = 2, 1.0 percent), cardiomyositis (*n* = 2, 1.0 percent), neurological complication (*n* = 7, 3.3 percent), and rhabdomyolysis (*n* = 13, 6.2 percent). The frequency of pneumothorax differed significantly among the four pneumonia subtypes (*P* = 0.004) ([Table 1](#T1){ref-type="table"}).

Laboratory Data on Admission {#s3e}
----------------------------

Laboratory data on admission (median, range) included a white blood cell count of 9,865/mm^3^ (1300-37,200), AST of 31 IU/L (9-2,380), ALT of 22 IU/L (5-1,135), LDH of 260 IU/L (26-4,695), BUN of 17 mg/dL (5-145), creatinine of 0.8 mg/dL (0.3-3.4), and CRP of 12.1 mg/dL (0.2-54.3). The values of serum BUN (*P* = 0.015), creatinine (*P* = 0.030), and CRP (*P* \< 0.001) differed significantly among the four pneumonia subtypes ([Table 1](#T1){ref-type="table"}).

Severity on Admission {#s3f}
---------------------

Overall, 56 patients (26.7 percent) had severe pneumonia. Severity tended to differ between the four groups (*P* = 0.069). Among the four pneumonia subtypes, the unclassified subtype included 13 patients with severe *flu-p* and comprised the highest number of severe cases.

Treatment and Outcomes {#s3g}
----------------------

Twenty-four patients received NI before admission, half of whom received NI within 48 hours after the onset of initial symptoms, and 91 patients received NI after admission. Overall, 115 (54.8 percent) patients received antiviral therapy either before or after admission, with 53 (46.1 percent) receiving NI within 48 hours of their initial symptoms. Antibiotics were administered to 68 patients before admission by local physicians and to 202 patients following admission, with 128 receiving guideline-concordant therapy \[[@R10]\]. Among the 210 patients with *flu-p*, discordant therapy included single β-lactams in 77 patients and a single macrolide in 1 patient. Among the 105 patients with mixed viral and bacterial or secondary bacterial pneumonia, discordant therapy included single β-lactams in 37 patients and a single macrolide in 1 patient. Corticosteroid therapy was administered in 24 (11.4 percent) patients, and 17 (8.1 percent) patients required mechanical ventilation. On admission, 56 (26.7 percent) patients were judged to have severe pneumonia, and 16 (7.6 percent) patients died. Mortality differed significantly among the four pneumonia subtypes (*P* = 0.022), with the unclassified pneumonia subtype showing the highest mortality (17.2 percent).

Factors Contributing to Severe Disease and Mortality {#s3h}
----------------------------------------------------

Univariate analysis found that advanced age (≥ 65 years), neurological disorders, acute kidney injury complicated with *flu-p*, and pneumonia subtypes (unclassified, compared with primary viral pneumonia) were independent factors associated with severity ([Table 4](#T4){ref-type="table"}). Multivariate analysis found that advanced age (≥ 65 years; odds ratio \[range\] 2.74 \[1.07-7.01\]), pneumonia subtypes (unclassified, compared with primary viral pneumonia \[3.31 (1.07-10.28)\]), diabetes mellitus (2.74 \[1.01-7.46\]), and acute kidney injury complicated with *flu-p* (14.69 \[1.34-161.38\]), were independent factors associated with severity. Administration of antibiotics or NI by local physicians before admission was not associated with the severity of pneumonia on admission.

A univariate analysis found that pneumonia subtypes (mixed viral and bacterial pneumonia and undifferentiated pneumonia compared with primary viral pneumonia), systemic steroids and immunosuppressant administration, complications of *flu-p* (pneumothorax and acute kidney injury), and severity on admission (severe) were independent factors associated with mortality ([Table 5](#T5){ref-type="table"}). Pneumonia subtypes (mixed viral and bacterial pneumonia \[9.73 (1.48-63.96)\] and undifferentiated pneumonia \[14.39 (1.68-123.44)\] compared with primary viral pneumonia), HCAP (3.95 \[1.11-14.03\]) (compared with community-acquired pneumonia), acute kidney injury complicated with *flu-p*(11.62 \[1.28-105.10\]), and severity on admission (severe) (6.39 \[1.96-20.86\]), were independent factors for non-survival by multivariate analysis. NI administration, number of antibiotics or concordance with the guideline, and corticosteroids administration had no significant effect on mortality.

As for mixed viral and bacterial pneumonia or secondary bacterial pneumonia, a univariate analysis found that old tuberculosis, acute kidney injury complicated with *flu-p*, and severity on admission (severe) were independent factors associated with mortality ([Table 6](#T6){ref-type="table"}). Acute kidney injury complicated with *flu-p* (19.71 \[1.32, 294.10\]) and severity on admission (severe) (7.31 \[1.57, 34.04\]) were independent factors for non-survival by multivariate analysis. NI administration, number of antibiotics or concordance with the guideline, and corticosteroids administration had no significant effect on mortality.

Discussion {#s4}
==========

We focused on clinical features and factors contributing to the severity and mortality of *flu-p* in this study. The age distribution, laboratory data, and complications varied in our patients with *flu-p*. Identified factors contributing to severity included advanced age (≥ 65 years), pneumonia subtypes (unclassified compared with primary viral pneumonia), diabetes mellitus, and acute kidney injury complicated with *flu-p*. Factors contributing to mortality included pneumonia subtypes (mixed viral and bacterial pneumonia and undifferentiated pneumonia compared with primary viral pneumonia), HCAP, acute kidney disease complicated with *flu-p*, and severity on admission (severe).

About half of our cases showed mixed viral and bacterial pneumonia or secondary bacterial pneumonia, whereas one third showed primary viral pneumonia. In the past, primary viral pneumonia in seasonal influenza was considered rare \[[@R14]\], but our previous study showed that 30 percent of patients with seasonal *flu-p* developed primary viral pneumonia. In addition, high rates of primary viral pneumonia in pH1N1 *flu-p* have been reported. For example, Perez-Padilla et al. \[[@R15]\]. reported it in all 18 of their cases (100 percent), Champunot et al. \[[@R16]\] in 92 percent, and Cui et al. \[[@R17]\]. in 84 percent of patients. These differences have been explained by a difference in the affinity of virus subtypes for the lung or the airways \[[@R18]\]. Our previous study showed a higher rate of primary viral pneumonia in patients with pH1N1 *flu-p* than in those with H3N2 or B *flu-p*\[[@R19]\]. Thus, it is predicted that the pattern of *flu-p* subtypes currently in vogue differs according to the epidemic viral subtypes year by year.

Mixed viral and bacterial pneumonia was an independent factor of mortality in this study. Bacterial pneumonia complicating influenza is well recognized as a severe manifestation of influenza; it accounted for a substantial number of deaths from the 1918 influenza pandemic \[[@R20]\]. Over the past decade, *S. pneumoniae* (29 to 48 percent) and *Staphylococcus aureus* (7 to 40 percent) have continued to be the dominant bacterial causes of influenza-associated bacterial pneumonia \[[@R1],[@R21]-[@R25]\]. We investigated pathogens of mixed infection with *flu-p* with cultures, urinary antigen tests, and paired sera, and *S. pneumoniae* was found most frequently, followed by *H. influenzae*, *M. pneumoniae*, and *C. pneumoniae*. Atypical pathogens were found in 9 percent of cases. In addition, we experienced two patients with invasive aspergillosis after influenza, both of whom died. Limited cases of invasive aspergillosis with influenza have been reported \[[@R26]\], and the prognosis was extremely poor \[[@R27]\]. Aggressive investigation of the presence of fungal infection is required when physicians encounter patients with *flu-p* who do not respond to administered empirical antibiotics. The mechanisms by which mixed infection occur are complex: for example, virus-induced changes in the respiratory tract \[[@R28]\], virus-induced cytopathology and resulting immunological impairment \[[@R29]\], and modification of the immune response either by diminishing the ability of the host to clear bacteria or by amplification of the inflammatory cascade \[[@R30]\]. The results of the present study emphasized the importance of mixed infection as a prognostic factor in *flu-p*.

Several complications of *flu-p* such as pneumothorax \[[@R31]\] or rhabdomyolysis \[[@R32]\] have been reported sporadically; however, the frequency of these complications is unclear. We reviewed radiographic or computed tomography findings, laboratory data, and medical records to clarify the exact frequency of the complications. In addition, we clarified that acute kidney injury was associated with the severity and prognosis of *flu-p*, and thus, physicians should attempt to detect and then manage these complications appropriately.

Several of our patients with *flu-p* received corticosteroid therapy \[[@R33]\]. Some studies indicate that corticosteroids seem to have potentially harmful effects. Some of our patients with primary viral pneumonia were diagnosed initially as having acute interstitial pneumonia or cryptogenic organizing pneumonia and received corticosteroid therapy. Lung biopsy of some of these patients showed histologic patterns of organizing pneumonia or acute lung injury \[[@R19]\], and in some cases, the patients responded only to corticosteroid therapy, whereas antiviral agents or antibiotics failed \[[@R33]\]. The diagnosis of these patients was subsequently corrected to *flu-p* after confirming positive PCR results from samples of bronchoalveolar lavage fluid or elevated antibody titers. We hypothesize that there is a group of patients for whom corticosteroid therapy is effective, but future studies are needed to confirm this hypothesis.

Risk factors contributing to disease severity include underlying conditions known to predispose to complications from seasonal influenza, with pregnancy, obesity, and immunosuppression additionally identified \[[@R2]\]. The present study showed advanced age (≥ 65 years), pneumonia subtypes (undifferentiated pneumonia compared with primary viral pneumonia), diabetes mellitus, and acute kidney injury complicated with *flu-p* to be additional risk factors. Anamnesis was not available from some patients with a severe condition, and these patients were classified into the "unclassified" group. Therefore, it may be natural that the "unclassified" pneumonia subtype group was independently associated with severity and mortality.

We did not investigate the long-term prognosis of the patients. However, several outcome studies have been conducted, and the mortality rates among the patients who survived the initial event of pneumonia were substantially higher than those in the control subjects \[[@R34]-[@R37]\]. This is thought to be associated with the increased incidence of pulmonary or cardiovascular complications. Furthermore, patients with more severe pneumonia have a higher risk of long-term mortality than patients with less severe pneumonia \[[@R34]\]. These findings suggest that the factors associated with severe pneumonia are also important in predicting prognosis after hospital discharge. Efforts to improve the prevention and management of pneumonia, especially in severe cases, are clearly necessary and may reduce the rate of long-term mortality.

The mortality rate of patients with *flu-p* in the present study was 7.6 percent, which is consistent with that reported in previous studies of 5.5 percent \[[@R38]\] to 29.4 percent \[[@R21]\]. Previous studies have suggested the following as prognostic factors: advanced age, Caucasian race, nursing home resident, chronic lung disease, cardiovascular disease, renal disease, immunosuppression, obesity, and lymphopenia not resolved after 5 days of treatment \[[@R2],[@R4]\]. We identified the following additional prognostic factors: pneumonia subtypes, HCAP, acute kidney injury complicated with *flu-p*, and severity on admission. Our results suggest the importance of classifying pneumonia and identifying complications of *flu-p* and disease severity on admission. Unclassified pneumonia subtype was independently associated with severity, and both this subtype and severe pneumonia as evaluated by ATS/IDSA severity criteria were prognostic factors of *flu-p*. Although the exact reason is unknown, this result may indicate that patients with unclassified pneumonia subtype had some factors that were not included in the ATS/IDSA severity criteria. We also found HCAP to be an independent prognostic factor. HCAP describes a patient population with frequent healthcare contacts that is not only at high risk of contracting resistant organisms but also elderly and frail. We previously reported that *flu-p* is the second leading cause of HCAP \[[@R8]\], but to our knowledge, only a few reports have investigated influenza virus in HCAP. The frequency of *flu-p* may be underestimated, and the results obtained in the present study suggest that *flu-p* is important in the patient population with HCAP.

The use of antibiotics or NI was not associated with the severity of pneumonia or mortality in this study although numerous reports have shown positive results with antibiotics or NI for pneumonia \[[@R39],[@R40]\]. We initially suspected the complexity of *flu-p* as a possible cause of this result. *Flu-p* can be classified into four types: primary viral pneumonia, secondary bacterial pneumonia, mixed viral and bacterial pneumonia, and unclassified subtype. For patients with secondary bacterial pneumonia and mixed viral and bacterial pneumonia, the significance of antibiotics is theoretically increased, whereas it is assumed that antibiotics have little effect on primary viral pneumonia. Therefore, we further analyzed the effect of concordant antibiotics therapy on patient outcome in the mixed viral and bacterial pneumonia and secondary bacterial pneumonia subtypes; however, no favorable effect of concordant antibiotics therapy on outcome was found. Two reasons are suggested for these results: first, the number of patients in the present study was small. There were only 16 non-survivors, and a limited number of prognostic factors could be identified statistically. Second, the frequency of atypical pathogens in mixed viral and bacterial or secondary infection was relatively lower than that in previous reports of CAP \[[@R7],[@R41]\]. Atypical pathogens were present in 9 percent of our *flu-p* patients and in only 2 of the non-survivors. Most of the patients receiving guideline-discordant treatment were treated with single β-lactams, and most pathogens in the mixed viral and bacterial or secondary bacterial pneumonias were covered. This may be a reason why guideline-concordant therapy had little effect on patient outcome in the present study.

This study has several limitations. We could collect data from medical records only from December 1999 through March 2016; thus, the numbers of patients included in both 1999 and 2016 are limited. Because this is a nonrandomized observational study, the level of confidence in the results is lessened, and a complete diagnostic workup to determine etiology was not possible in every patient. Further, RT-PCR was performed only in a limited number of patients. To assess factors related to severity and prognosis, we selected factors associated with patient demographics, complications, and those of CAP/HCAP or *flu-p* identified in previous studies for univariate and multivariate analysis. Several profiles of immune cells or cytokines have been identified as key factors of *flu-p* in recent studies \[[@R42]-[@R45]\], but we could not assess the significance of these factors because of the retrospective nature of the present study. Finally, this was a single-center study, and the results may not be applicable in other settings.

In conclusion,*flu-p* presents a variety of clinical features. We identified characteristics of *flu-p* and factors contributing to the severity of and mortality from *flu-p.* Knowledge of patient profiles and underlying diseases, mixed infections and complications, and identification of disease severity on admission are required for the adequate management of *flu-p*.
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*flu-p*

:   influenza-associated pneumonia

HCAP

:   healthcare-associated pneumonia

CAP

:   community-acquired pneumonia

NI

:   neuraminidase inhibitors

PS

:   performance status

RT-PCR

:   reverse transcription polymerase chain reaction

COPD

:   chronic obstructive pulmonary disease

###### Patient Characteristics.

  **Characteristic**                                   **Total**           **Primary viral pneumonia**   **Mixed viral and bacterial pneumonia**   **Secondary pneumonia**   **Unclassified**    ***P*-value**
  ---------------------------------------------------- ------------------- ----------------------------- ----------------------------------------- ------------------------- ------------------- ---------------
                                                                           N = 76                        N = 71                                    N = 34                    N = 29              
  Age (years)                                          66.7 ± 15.63        66.7 ± 15.91                  67.4 ± 14.44                              61.7 ± 16.91              71.0 ± 15.34        0.118
  Male sex                                             151 (71.9%)         59 (77.6%)                    55 (77.5%)                                22 (64.7%)                15 (51.7%)          0.029
  Smoking history                                      134 (63.8%)         52 (68.4%)                    46 (64.8%)                                22 (64.7%)                14 (48.3%)          0.287
  Vaccination history                                                                                                                                                                            
   23-valent polysaccharide vaccine (within 5 years)                                                                                                                                             
   Yes                                                 7 (3.3%)            3 (3.9%)                      2 (2.8%)                                  1 (2.9%)                  1 (3.4%)            0.555
   No                                                  201 (95.7%)         73 (96.1%)                    69 (97.2%)                                32 (94.1%)                27 (93.1%)          
   Unknown                                             2 (1.0%)            0 (0.0%)                      0 (0.0%)                                  1 (2.9%)                  1 (3.4%)            
   Influenza vaccine (within one year)                                                                                                                                                           
   Yes                                                 31 (14.8%)          10 (13.2%)                    10 (14.1%)                                7 (20.6%)                 4 (13.8%)           0.012
   No                                                  129 (61.4%)         57 (75.0%)                    44 (62.0%)                                15 (44.1%)                13 (44.8%)          
   Unknown                                             50 (23.8%)          9 (11.8%)                     17 (23.9%)                                12 (35.3%)                12 (41.4%)          
  CAP/HCAP                                             64 (30.5%)          25 (32.9%)                    23 (32.4%)                                6 (17.6%)                 10 (34.5%)          0.363
  Viral subtypes                                                                                                                                                                                 
   pH1N1                                               48 (22.9%)          19 (25.0%)                    21 (29.6%)                                6 (17.6%)                 2 (6.9%)            0.004
   H3N2                                                8 (3.8%)            1 (1.3%)                      2 (2.8%)                                  3 (8.8%)                  2 (6.9%)            
   sH1N1                                               23 (11.0%)          16 (21.1%)                    5 (7.0%)                                  2 (5.9%)                  0 (0.0%)            
   Undifferentiated                                    85 (40.5%)          27 (35.5%)                    25 (35.2%)                                18 (52.9%)                15 (51.7%)          
   B                                                   46 (21.9%)          13 (17.1%)                    18 (25.4%)                                5 (14.7%)                 10 (34.5%)          
  Comorbidity                                                                                                                                                                                    
   Chronic pulmonary disease                           95 (45.2%)          31 (40.8%)                    34 (47.9%)                                14 (41.2%)                16 (55.2%)          0.534
   Chronic obstructive pulmonary disease               41 (19.5%)          11 (14.5%)                    22 (31.0%)                                4 (11.8%)                 4 (13.8%)           0.028
   Asthma                                              20 (9.5%)           11 (14.5%)                    2 (2.8%)                                  4 (11.8%)                 3 (10.3%)           0.107
   Bronchiectasis                                      10 (4.8%)           0 (0.0%)                      8 (11.3%)                                 0 (0.0%)                  2 (6.9%)            0.006
   Nontuberculous mycobacteriosis                      4 (1.9%)            0 (0.0%)                      3 (4.2%)                                  0 (0.0%)                  1 (3.4%)            0.208
   Old pulmonary tuberculosis                          14 (6.7%)           5 (6.6%)                      1 (1.4%)                                  5 (14.7%)                 3 (10.3%)           0.062
   Chronic pulmonary aspergillosis                     2 (1.0%)            0 (0.0%)                      0 (0.0%)                                  1 (2.9%)                  1 (3.4%)            0.191
   Interstitial pneumonia                              15 (7.1%)           6 (7.9%)                      4 (5.6%)                                  2 (5.9%)                  3 (10.3%)           0.840
   Post lung cancer operation                          4 (1.9%)            3 (3.9%)                      0 (0.0%)                                  0 (0.0%)                  1 (3.4%)            0.250
   Hypertension                                        26 (12.4%)          7 (9.2%)                      10 (14.1%)                                4 (11.8%)                 5 (17.2%)           0.674
   Chronic cardiac disease                             30 (14.3%)          15 (19.7%)                    6 (8.5%)                                  5 (14.7%)                 4 (13.8%)           0.281
   Congestive heart failure                            12 (5.7%)           5 (6.6%)                      3 (4.2%)                                  1 (2.9%)                  3 (10.3%)           0.565
   Ischemic heart disease                              14 (6.7%)           7 (9.2%)                      4 (5.6%)                                  3 (8.8%)                  0 (0.0%)            0.356
   Valvular heart disease                              5 (2.4%)            4 (5.3%)                      0 (0.0%)                                  1 (2.9%)                  0 (0.0%)            0.158
   Arrhythmia                                          6 (2.9%)            3 (3.9%)                      1 (1.4%)                                  1 (2.9%)                  1 (3.4%)            0.825
   Diabetes mellitus                                   27 (12.9%)          9 (11.8%)                     13 (18.3%)                                2 (5.9%)                  3 (10.3%)           0.309
   Post surgery of upper digestive system              4 (1.9%)            2 (2.6%)                      2 (2.8%)                                  0 (0.0%)                  0 (0.0%)            0.625
   Chronic liver disease                               7 (3.3%)            2 (2.6%)                      2 (2.8%)                                  2 (5.9%)                  1 (3.4%)            0.835
   Connective tissue disease                           9 (4.3%)            3 (3.9%)                      4 (5.6%)                                  2 (5.9%)                  0 (0.0%)            0.605
   Psychiatric disease                                 6 (2.9%)            2 (2.6%)                      3 (4.2%)                                  0 (0.0%)                  1 (3.4%)            0.676
   Malignancy                                          0 (0.0%)            0 (0.0%)                      0 (0.0%)                                  0 (0.0%)                  0 (0.0%)            \-
   Alcoholism                                          2 (1.0%)            0 (0.0%)                      2 (2.8%)                                  0 (0.0%)                  0 (0.0%)            0.267
   Steroid or immunosuppressant use                    20 (9.5%)           6 (7.9%)                      8 (11.3%)                                 5 (14.7%)                 1 (3.4%)            0.426
   Chronic kidney disease                              0 (0.0%)            0 (0.0%)                      0 (0.0%)                                  0 (0.0%)                  0 (0.0%)            \-
   Neurological disorders                              17 (8.1%)           5 (6.6%)                      8 (11.3%)                                 0 (0.0%)                  4 (13.8%)           0.141
  Laboratory data                                                                                                                                                                                
   WBC                                                 11202.4 ± 6339.69   10382.9 ± 5636.04             12069.0 ± 7507.49                         11985.3 ± 5005.10         10310.3 ± 6260.33   0.298
   AST                                                 57.8 ± 169.89       77.8 ± 273.60                 53.2 ± 61.10                              38.6 ± 39.35              39.1 ± 30.75        0.599
   LDH                                                 334.1 ± 406.36      397.0 ± 641.92                312.9 ± 155.89                            285.9 ± 174.42            277.0 ± 95.35       0.384
   BUN                                                 21.5 ± 17.29        18.7 ± 11.03                  26.3 ± 24.82                              15.8 ± 6.93               22.9 ± 11.76        0.015
   Cre                                                 0.9 ± 0.44          0.9 ± 0.32                    1.0 ± 0.61                                0.7 ± 0.24                0.9 ± 0.33          0.030
   CRP                                                 14.0 ± 10.33        11.8 ± 8.24                   18.0 ± 12.14                              14.8 ± 10.09              9.4 ± 7.06          \<.001
  Complications                                                                                                                                                                                  
   Pneumothorax                                        4 (1.9%)            0 (0.0%)                      1 (1.4%)                                  0 (0.0%)                  3 (10.3%)           0.004
   Pleuritis or pyothorax                              2 (1.0%)            0 (0.0%)                      2 (2.8%)                                  0 (0.0%)                  0 (0.0%)            0.267
   Acute kidney disease                                7 (3.3%)            2 (2.6%)                      5 (7.0%)                                  0 (0.0%)                  0 (0.0%)            0.150
   Acute pulmonary thromboembolism                     2 (1.0%)            2 (2.6%)                      0 (0.0%)                                  0 (0.0%)                  0 (0.0%)            0.313
   Myocarditis                                         2 (1.0%)            1 (1.3%)                      0 (0.0%)                                  1 (2.9%)                  0 (0.0%)            0.476
   Neurological symptoms (encephalitis, meningitis)    7 (3.3%)            5 (6.6%)                      2 (2.8%)                                  0 (0.0%)                  0 (0.0%)            0.194
   Rhabdomyolysis                                      13 (6.2%)           6 (7.9%)                      7 (9.9%)                                  0 (0.0%)                  0 (0.0%)            0.103
  Performance status                                                                                                                                                                             
   0                                                   102 (48.6%)         41 (53.9%)                    31 (43.7%)                                23 (67.6%)                7 (24.1%)           0.027
   1-2                                                 42 (20.0%)          11 (14.5%)                    18 (25.4%)                                6 (17.6%)                 7 (24.1%)           
   3-4                                                 20 (9.5%)           5 (6.6%)                      8 (11.3%)                                 3 (8.8%)                  4 (13.8%)           
   Unknown                                             46 (21.9%)          19 (25.0%)                    14 (19.7%)                                2 (5.9%)                  11 (37.9%)          
  Severe                                               56 (26.7%)          17 (22.4%)                    20 (28.2%)                                6 (17.6%)                 13 (44.8%)          0.069
  Mortality                                            16 (7.6%)           1 (1.3%)                      8 (11.3%)                                 2 (5.9%)                  5 (17.2%)           0.022

AST, aspartate transaminase; BUN, blood urea nitrogen; CAP, community-acquired pneumonia; Cre, creatinine; CRP, C-reactive protein; HCAP, healthcare-associated pneumonia; LDH, lactate dehydrogenase; WBC, white blood cells.

###### Diagnostic methods and patient results (*n* = 210).

  **Method**                        **No. of episodes studied**   **No. of positive diagnostic studies (%)**   
  --------------------------------- ----------------------------- -------------------------------------------- ---------------------
                                                                  **Other than influenza virus**               **Influenza virus**
  Paired sera                       157                           13                                           82
  Rapid influenza diagnostic test   208                           \-                                           154
  RT-PCR                            12                            \-                                           12
  Urinary antigen                                                                                              
   *Streptococcus pneumoniae*       178                           48                                           \-
   *Legionella* sp.                 178                           2                                            \-
  Culture                                                                                                      
   Sputum                           176                           41                                           \-
   Transbronchial aspirate          10                            2                                            \-
   Protected specimen brush         2                             0                                            \-
   Bronchial washing                3                             0                                            \-
   Bronchoalveolar lavage fluid     16                            2                                            \-
   Blood                            140                           3                                            \-
   Pleural fluid                    3                             0                                            \-

RT-PCR, reverse-transcription polymerase chain reaction.

###### Mixed infection with influenza virus.

                                                             **Total**   **% of 210 patients**   **Severe**   **Non-survivors**
  ---------------------------------------------------------- ----------- ----------------------- ------------ -------------------
  Two pathogens                                                                                               
   *Streptococcus pneumoniae* + *Chlamydophila pneumoniae*   3           1.4                     2            0
   *S. pneumoniae* + *Mycoplasma pneumoniae*                 2           1.0                     0            0
   *S. pneumoniae* + *MSSA*                                  2           1.0                     2            1
   *S. pneumoniae* + *Haemophilus influenzae*                1           0.5                     0            0
   *S. pneumoniae* + *Legionella* spp.                       1           0.5                     0            0
   *S. pneumoniae* + *Staphylococcus haemolyticus*           1           0.5                     0            0
   *S. pneumoniae* + *Aspergillus fumigatus*                 1           0.5                     1            1
   *P. aeruginosa* + *Acinetobacter baumannii*               1           0.5                     0            0
  Single pathogen                                                                                             
   *S. pneumoniae*                                           44          21.0                    9            1
   *H. influenza*                                            9           4.3                     3            1
   *M. pneumoniae*                                           6           2.9                     1            1
   *GNEB*                                                    4           1.9                     2            1
   *C. pneumoniae*                                           4           1.9                     1            1
   *Legionella* sp.                                          3           1.4                     0            0
   *P. aeruginosa*                                           2           1.0                     1            0
   *MRSA*                                                    2           1.0                     1            1
   *MSSA*                                                    1           0.5                     0            0
   *Moraxella catarrhalis*                                   1           0.5                     0            0
   *S. pyogenes*                                             1           0.5                     0            0
   *A. fumigatus*                                            2           1.0                     1            1

GNEB, gram-negative enterobacilli; MSSA, methicillin-sensitive *Staphylococcus aureus*; MRSA, methicillin-resistant *Staphylococcus aureus*.

###### Univariate and multivariate analyses of factors contributing to severe pneumonia.

                                                                                                                                                                              **Univariate analysis**   **Multivariate analysis**
  -------------------------------------------------------------------------- --------------------------- ---------------- ------------------- --------------------- --------- ------------------------- ---------------------------
  Sex                                                                        Male                        151 38 (25.2%)   0.77 (0.39, 1.49)   0.432                                                     
  Age                                                                        65-                         130              42 (32.3%)          2.25 (1.14, 4.46)     0.020     2.74 (1.07, 7.01)         0.036
                                                                             \<65                        80               14 (17.5%)                                                                    
  Body mass index                                                            BMI unknown                 78               27 (34.6%)          2.19 (1.05, 4.55)     0.036     1.48 (0.60, 3.65)         0.391
                                                                             BMI≥25                      22               5 (22.7%)           1.22 (0.39, 3.82)     0.738     1.31 (0.34, 5.01)         0.697
                                                                             18\>BMI                     33               9 (27.3%)           1.55 (0.60, 4.01)     0.367     1.13 (0.35, 3.62)         0.839
                                                                             25\>BMI≥18                  77               15 (19.5%)          Reference                       Reference                 
  Vaccination history                                                                                                                                                                                   
   23-valent pneumococcal polysaccharide vaccination within 5 years          Unknown                     2                0 (0.0%)                                                                      
                                                                             No                          201              54 (26.9%)          0.92 (0.17, 4.87)     0.920                               
                                                                             Yes                         7                2 (28.6%)                                                                     
   Influenza vaccination within one year                                     Unknown                     50               11 (22.0%)          0.81 (0.28, 2.31)     0.695                               
                                                                             No                          129              37 (28.7%)          1.16 (0.47, 2.82)     0.749                               
                                                                             Yes                         31               8 (25.8%)           Reference                                                 
  Prior antibiotic treatment                                                 No                          142              43 (30.3%)          1.84 (0.91, 3.71)     0.090     1.40 (0.61, 3.20)         0.423
  Neuraminidase inhibitors by local physicians                               No                          186              52 (28.0%)          1.94 (0.41, 9.16)     0.402                               
                                                                             ≥48 h                       12               2 (16.7%)           1.00 (0.12, 8.56)     1.000                               
                                                                             \<48 h                      12               2 (16.7%)           Reference                                                 
  Pneumonia subtype                                                          Mixed viral and bacterial   71               20 (28.2%)          1.36 (0.64, 2.87)     0.419     1.24 (0.39, 3.97)         0.717
                                                                             Secondary bacterial         34               6 (17.6%)           0.74 (0.26, 2.09)     0.574     1.56 (0.42, 5.86)         0.508
                                                                             Unclassified                29               13 (44.8%)          2.82 (1.14, 7.00)     0.025     3.31 (1.07, 10.28)        0.038
                                                                             Primary viral               76               17 (22.4%)          Reference                       Reference                 
  Viral subtype                                                              A/H1N1 seasonal             8                1 (12.5%)           0.48 (0.05, 4.34)     0.514     0.71 (0.07, 7.23)         0.770
                                                                             pH1N1                       23               5 (21.7%)           0.93 (0.28, 3.10)     0.912     2.88 (0.64, 12.96)        0.168
                                                                             A/Undifferentiated          85               28 (32.9%)          1.65 (0.73, 3.72)     0.225     1.95 (0.71, 5.38)         0.196
                                                                             B                           46               11 (23.9%)          1.06 (0.41, 2.75)     0.909     1.05 (0.34, 3.30)         0.928
                                                                             A/H3N2                      48               11 (22.9%)          Reference                       Reference                 
  Mixed infection                                                            Yes                         87               22 (25.3%)          0.89 (0.47, 1.65)     0.704     1.20 (0.44, 3.28)         0.729
  Comorbidities                                                                                                                                                                                         
   Chronic pulmonary diseases                                                Yes                         95               25 (26.3%)          0.97 (0.52, 1.79)     0.917     0.92 (0.44, 1.94)         0.828
   COPD                                                                      Yes                         41               10 (24.4%)          0.86 (0.39, 1.90)     0.713                               
   Asthma                                                                    Yes                         20               3 (15.0%)           0.46 (0.13, 1.62)     0.225                               
   Bronchiectasis                                                            Yes                         10               3 (30.0%)           1.19 (0.30, 4.77)     0.807                               
   Pulmonary NTM                                                             Yes                         4                0 (0.0%)                                                                      
   Interstitial pneumonia                                                    Yes                         15               6 (40.0%)           1.93 (0.66, 5.71)     0.232                               
   Hypertension                                                              Yes                         26               9 (34.6%)           1.54 (0.64, 3.70)     0.330                               
   Chronic cardiac diseases                                                  Yes                         30               7 (23.3%)           0.81 (0.33, 2.02)     0.656                               
   Congestive heart failure                                                  Yes                         12               4 (33.3%)           1.40 (0.41, 4.86)     0.592                               
   Ischemic heart diseases                                                   Yes                         14               2 (14.3%)           0.44 (0.09, 2.02)     0.290                               
   Diabetes mellitus                                                         Yes                         27               11 (40.7%)          2.11 (0.91, 4.87)     0.081     2.74 (1.01, 7.46)         0.048
   Post surgery of upper digestive system                                    Yes                         4                2 (50.0%)           2.81 (0.39, 20.46)    0.307                               
   Chronic liver diseases                                                    Yes                         7                1 (14.3%)           0.45 (0.05, 3.81)     0.463                               
   Connective tissue diseases                                                Yes                         9                1 (11.1%)           0.33 (0.04, 2.71)     0.304                               
   Immunosuppression due to systemic corticosteroids or immunosuppressants   Yes                         20               4 (20.0%)           0.66 (0.21, 2.08)     0.481                               
   Malignancy                                                                Yes                         0                0 (0.0%)                                                                      
   Alcoholism                                                                Yes                         2                0 (0.0%)                                                                      
   CKD                                                                       Yes                         0                0 (0.0%)                                                                      
   Neurological disorders                                                    Yes                         17               9 (52.9%)           3.49 (1.28, 9.57)     0.015     2.38 (0.67, 8.49)         0.180
  Smoking history                                                            Yes                         134              31 (23.1%)          0.61 (0.33, 1.15)     0.126                               
  Long-term oxygen therapy                                                   Yes                         12               3 (25.0%)           0.91 (0.24, 3.50)     0.893                               
  HCAP/CAP                                                                   HCAP                        64               19 (29.7%)          1.24 (0.65, 2.39)     0.513                               
  Performance status                                                         Unknown                     46               21 (45.7%)          3.92 (1.81, 8.48)     \<0.001   2.32 (0.86, 6.24)         0.095
                                                                             PS 3-4                      20               6 (30.0%)           2.00 (0.68, 5.91)     0.210     0.68 (0.16, 2.85)         0.600
                                                                             PS 1-2                      42               11 (26.2%)          1.66 (0.70, 3.90)     0.248     1.20 (0.43, 3.35)         0.734
                                                                             PS 0                        102              18 (17.6%)          Reference                       Reference                 
  Charlson Comorbidity Index                                                 High, Very high             8                3 (37.5%)           2.01 (0.44, 9.16)     0.367                               
                                                                             Medium                      115              33 (28.7%)          1.35 (0.71, 2.56)     0.362                               
                                                                             Low                         87               20 (23.0%)          Reference                                                 
  Bacteremia                                                                 Yes                         3                1 (33.3%)           1.38 (0.12, 15.54)    0.793                               
  Complications                                                                                                                                                                                         
   Pneumothorax                                                              Yes                         4                3 (75.0%)           8.66 (0.88, 85.01)    0.064                               
   Pleuritis or pyothorax                                                    Yes                         2                1 (50.0%)           2.78 (0.17, 45.20)    0.473                               
   Acute kidney disease                                                      Yes                         7                6 (85.7%)           19.69 (3.98, 97.49)   \<0.001   14.69 (1.34, 161.38)      0.028
   Acute pulmonary thromboembolism                                           Yes                         2                0 (0.0%)                                                                      
   Myocarditis                                                               Yes                         2                2 (100.0%)                                                                    
   Neurological symptoms (encephalitis, meningitis)                          Yes                         7                3 (42.9%)           2.12 (0.46, 9.80)     0.334                               
   Rhabdomyolysis                                                            Yes                         13               7 (53.8%)           1.41 (0.23, 8.83)     0.711     3.16 (0.82, 12.14)        0.094

CAP, community-acquired pneumonia; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; HCAP, healthcare-associated pneumonia; NTM, nontuberculous mycobacteriosis.

###### Univariate and multivariate analyses of factors contributing to mortality.

                                                                                                                                                                   **Univariate analysis**   **Multivariate analysis**
  -------------------------------------------------------------------------- --------------------------- ----- ------------------- ---------------------- -------- ------------------------- ---------------------------
  Sex                                                                        Male                        151   12 (7.9%)           1.11 (0.36, 3.42)      0.862                              
  Age                                                                        65-                         130   11 (8.5%)           1.32 (0.46, 3.82)      0.607                              
  Body mass index                                                            Unknown                     78    10 (12.8%)          4.63 (1.11, 19.27)     0.035    1.38 (0.31, 6.11)         0.668
                                                                             ≥25                         22    2 (9.1%)            3.68 (0.58, 23.34)     0.167    2.26 (0.31, 16.42)        0.420
                                                                             18\>                        33    2 (6.1%)            2.40 (0.39, 14.80)     0.347    0.54 (0.07, 4.40)         0.566
                                                                             25\>BMI≥18                  77    2 (2.6%)            Reference                       Reference                 
   23-valent pneumococcal polysaccharide vaccination within 5 years          Unknown                     2     0 (0.0%)            3.00 (0.02, 370.45)    0.655                              
                                                                             No                          201   16 (8.0%)           1.33 (0.06, 29.67)     0.855                              
   Influenza vaccination within one year                                     Unknown                     50    2 (4.0%)            1.05 (0.13, 8.58)      0.965                              
                                                                             No                          129   13 (10.1%)          2.36 (0.41, 13.68)     0.340                              
  Prior antibiotic treatment                                                 No                          142   8 (5.6%)            0.45 (0.16, 1.23)      0.119                              
  Pneumonia subtype                                                          Mixed viral and bacterial   71    8 (11.3%)           6.74 (1.14, 39.93)     0.036    9.73 (1.48, 63.96)        0.018
                                                                             Secondary bacterial         34    2 (5.9%)            3.87 (0.48, 31.17)     0.203    8.88 (0.90, 87.99)        0.062
                                                                             Unclassified                29    5 (17.2%)           11.30 (1.73, 73.99)    0.011    14.39 (1.68, 123.44)      0.015
                                                                             Primary viral               76    1 (1.3%)            Reference                       Reference                 
  Viral subtype                                                              A/H1N1 seasonal             8     0 (0.0%)            1.86 (0.06, 58.20)     0.723    2.97 (0.11, 82.97)        0.521
                                                                             pH1N1                       23    1 (4.3%)            2.11 (0.20, 22.25)     0.534    9.77 (0.65, 147.70)       0.100
                                                                             A/Undifferentiated          85    11 (12.9%)          4.89 (0.84, 28.32)     0.077    4.16 (0.63, 27.60)        0.140
                                                                             B                           46    3 (6.5%)            2.55 (0.35, 18.39)     0.354    2.18 (0.26, 18.18)        0.470
                                                                             A/H3N2                      48    1 (2.1%)            Reference                       Reference                 
  Mixed infection                                                            Yes                         87    9 (10.3%)           1.88 (0.69, 5.13)      0.218                              
  Comorbidities                                                                                                                                                                              
   Chronic pulmonary diseases                                                Yes                         95    8 (8.4%)            1.23 (0.45, 3.33)      0.686    1.94 (0.60, 6.25)         0.265
   COPD                                                                      Yes                         41    2 (4.9%)            0.68 (0.17, 2.76)      0.588                              
   Asthma                                                                    Yes                         20    0 (0.0%)            0.26 (0.01, 4.78)      0.363                              
   Bronchiectasis                                                            Yes                         10    1 (10.0%)           1.89 (0.29, 12.38)     0.507                              
   Pulmonary NTM                                                             Yes                         4     0 (0.0%)            1.28 (0.05, 34.96)     0.882                              
   Interstitial pneumonia                                                    Yes                                                                                                             
   Old tuberculosis                                                          Yes                         14    3 (21.4%)           4.14 (1.07, 16.07)     0.040                              
   Hypertension                                                              Yes                         26    2 (7.7%)            1.20 (0.29, 5.02)      0.803                              
   Chronic cardiac diseases                                                  Yes                         30    3 (10.0%)           1.58 (0.45, 5.57)      0.478                              
   Congestive heart failure                                                  Yes                         12    2 (16.7%)           3.03 (0.65, 14.03)     0.156                              
   Ischemic heart diseases                                                   Yes                         14    1 (7.1%)            1.30 (0.21, 8.05)      0.777                              
   Arrythmias                                                                Yes                         6     1 (16.7%)           3.33 (0.44, 25.08)     0.242                              
   Diabetes mellitus                                                         Yes                         27    2 (7.4%)            1.15 (0.27, 4.78)      0.852                              
   Post surgery of upper digestive system                                    Yes                         4     1 (25.0%)           5.30 (0.59, 47.82)     0.138                              
   Chronic liver diseases                                                    Yes                         7     0 (0.0%)            0.76 (0.03, 16.84)     0.861                              
   Connective tissue diseases                                                Yes                         9     0 (0.0%)            0.59 (0.03, 12.37)     0.735                              
   Immunosuppression due to systemic corticosteroids or immunosuppressants   Yes                         20    4 (20.0%)           3.89 (1.16, 13.10)     0.028                              
   Malignancy                                                                Yes                         0     0 (0.0%)                                                                      
   Alcoholism                                                                Yes                         2     1 (50.0%)           12.48 (0.74, 209.29)   0.079                              
   CKD                                                                       Yes                         0     0 (0.0%)                                                                      
   Neurological disorders                                                    Yes                         17    3 (17.6%)           3.23 (0.86, 12.12)     0.083                              
  Smoking history                                                            Yes                         134   9 (6.7%)            0.70 (0.26, 1.92)      0.490                              
  Long-term oxygen therapy                                                   Yes                         12    2 (16.7%)           3.03 (0.65, 14.03)     0.156                              
  HCAP/CAP                                                                   HCAP                        64    8 (12.5%)           2.45 (0.90, 6.70)      0.081    3.95 (1.11, 14.03)        0.033
  Performance status                                                         Unknown                     46    6 (13.0%)           2.84 (0.85, 9.47)      0.088    1.30 (0.27, 6.37)         0.744
                                                                             PS 3-4                      20    2 (10.0%)           2.40 (0.48, 11.93)     0.286    0.75 (0.09, 6.26)         0.794
                                                                             PS 1-2                      42    3 (7.1%)            1.57 (0.39, 6.39)      0.528    0.71 (0.13, 3.95)         0.691
                                                                             PS 0                        102   5 (4.9%)            Reference                       Reference                 
  Charlson Comorbidity Index                                                 High, Very high             8     1 (12.5%)           3.00 (0.39, 23.35)     0.294                              
                                                                             Medium                      115   10 (8.7%)           1.49 (0.51, 4.38)      0.466                              
                                                                             Low                         87    5 (5.7%)            Reference                                                 
  Bacteremia                                                                 Yes                         3     0 (0.0%)            1.66 (0.05, 52.69)     0.775                              
  Complications                                                                                                                                                                              
   Pneumothorax                                                              Yes                         4     2 (50.0%)           13.27 (1.74, 101.23)   0.013                              
   Pleuritis or pyothorax                                                    Yes                         2     1 (50.0%)           12.48 (0.74, 209.29)   0.079                              
   Acute kidney disease                                                      Yes                         7     4 (57.1%)           19.69 (3.98, 97.49)    \<.001   11.62 (1.28, 105.10)      0.029
   Acute pulmonary thromboembolism                                           Yes                         2     0 (0.0%)            2.33 (0.05, 99.51)     0.658                              
   Myocarditis                                                               Yes                         2     0 (0.0%)            2.33 (0.05, 99.51)     0.658                              
   Neurological symptoms (encephalitis, meningitis)                          Yes                         7     1 (14.3%)           2.81 (0.39, 20.08)     0.304                              
   Rhabdomyolysis                                                            Yes                         13    1 (7.7%)            1.41 (0.23, 8.83)      0.711                              
  Severity                                                                   Severe                      56    13 (23.2%)          13.43 (3.93, 45.90)    \<.001   6.39 (1.96, 20.86)        0.002
  Concordance with CAP guideline-recommended treatment                       Discordant                  74    7 (9.5%)            1.49 (0.54, 4.08)      0.437                              
  Number of initial antibiotics                                              ≥2                          135   9 (6.7%)            0.69 (0.25, 1.88)      0.463                              
  Neuraminidase inhibitors                                                   No                          53    3 (5.7%)            0.51 (0.14, 1.79)      0.293                              
                                                                             ≥48 h                       62    2 (3.2%)            0.30 (0.07, 1.25)      0.099                              
                                                                             \<48 h                      95    1+E4:E691 (11.6%)   Reference                                                 

CAP, community-acquired pneumonia; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; HCAP, healthcare-associated pneumonia; NTM, nontuberculous mycobacteriosis.

###### Univariate and multivariate analyses of factors contributing to mortality among mixed viral and bacterial pneumonia and secondary bacterial pneumonia.

                                                                                                                                                     **Univariate analysis**   **Multivariate analysis**
  -------------------------------------------------------------------------- -------------------- ----- ------------ ---------------------- -------- ------------------------- ---------------------------
  Sex                                                                        Male                 77    7 (9.1%)     0.78 (0.20, 3.04)      0.715                              
  Age                                                                        65-                  59    6 (10.2%)    1.15 (0.32, 4.13)      0.833                              
  Body mass index                                                            BMI unknown          41    7 (17.1%)    5.58 (0.89, 34.96)     0.066    2.44 (0.34, 17.59)        0.375
                                                                             ≥25                  10    2 (20.0%)    7.55 (0.82, 69.32)     0.074    3.17 (0.26, 38.63)        0.366
                                                                             18\>                 15    0 (0.0%)     0.83 (0.03, 23.48)     0.912    0.92 (0.04, 21.50)        0.957
                                                                             25\>BMI≥18           39    1 (2.6%)                                     Reference                 
  Vaccination History                                                                                                                                                          
   23-valent pneumococcal polysaccharide vaccination within 5 years          Unknown              1     0 (0.0%)                                                               
                                                                             No                   101   10 (9.9%)    0.80 (0.02, 26.10)     0.902                              
   Influenza vaccination within one year                                     Unknown              29    1 (3.4%)     0.58 (0.05, 6.36)      0.655                              
                                                                             No                   59    8 (13.6%)    1.82 (0.28, 11.77)     0.532                              
  Prior antibiotic treatment                                                 No                   67    4 (6.0%)     0.35 (0.10, 1.28)      0.114                              
  Viral subtype                                                              A/H1N1 seasonal      5     0 (0.0%)     1.61 (0.04, 58.00)     0.796    3.67 (0.08, 162.70)       0.502
                                                                             pH1N1                7     1 (14.3%)    4.08 (0.32, 51.24)     0.277    12.00 (0.60, 239.34)      0.104
                                                                             A/Undifferentiated   43    6 (14.0%)    3.06 (0.47, 19.97)     0.242    2.47 (0.30, 20.32)        0.399
                                                                             B                    23    2 (8.7%)     2.05 (0.24, 17.53)     0.510    3.69 (0.38, 35.61)        0.259
                                                                             A/H3N2               27    1 (3.7%)     Reference                       Reference                 
  Comorbidities                                                                                                                                                                
   Chronic pulmonary diseases                                                Yes                  48    5 (10.4%)    1.21 (0.34, 4.26)      0.770    3.18 (0.64, 15.87)        0.158
   COPD                                                                      Yes                  26    1 (3.8%)     0.44 (0.07, 2.67)      0.370                              
   Asthma                                                                    Yes                  6     0 (0.0%)     0.66 (0.03, 15.65)     0.794                              
   Bronchiectasis                                                            Yes                  8     1 (12.5%)    1.86 (0.26, 13.46)     0.537                              
   Pulmonary NTM                                                             Yes                  3     0 (0.0%)     1.26 (0.04, 40.90)     0.897                              
   Old tuberculosis                                                          Yes                  6     3 (50.0%)    12.33 (2.11, 72.16)    0.005                              
   Interstitial pneumonia                                                    Yes                  6     0 (0.0%)     0.66 (0.03, 15.65)     0.794                              
   Hypertension                                                              Yes                  14    1 (7.1%)     0.97 (0.15, 6.27)      0.970                              
   Chronic cardiac diseases                                                  Yes                  11    2 (18.2%)    2.68 (0.53, 13.51)     0.233                              
   Congestive heart failure                                                  Yes                  4     1 (25.0%)    4.17 (0.44, 39.24)     0.212                              
   Ischemic heart diseases                                                   Yes                  7     1 (14.3%)    2.17 (0.29, 16.28)     0.450                              
   Arrythmias                                                                Yes                  2     0 (0.0%)     1.78 (0.04, 77.55)     0.765                              
   Diabetes mellitus                                                         Yes                  15    2 (13.3%)    1.80 (0.38, 8.59)      0.462                              
   Post surgery of upper digestive system                                    Yes                  2     1 (50.0%)    9.94 (0.57, 172.22)    0.114                              
   Chronic liver diseases                                                    Yes                  4     0 (0.0%)     0.97 (0.03, 27.03)     0.985                              
   Connective tissue diseases                                                Yes                  6     0 (0.0%)     0.66 (0.03, 15.65)     0.794                              
   Immunosuppression due to systemic corticosteroids or immunosuppressants   Yes                  13    2 (15.4%)    2.16 (0.44, 10.56)     0.341                              
   Malignancy                                                                Yes                  0     0 (0.0%)                                                               
   Alcoholism                                                                Yes                  2     1 (50.0%)    9.94 (0.57, 172.22)    0.114                              
   CKD                                                                       Yes                  0     0 (0.0%)                                                               
   Neurological disorders                                                    Yes                  8     0 (0.0%)     0.49 (0.02, 10.80)     0.651                              
  Smoking history                                                            Yes                  68    6 (8.8%)     0.77 (0.21, 2.80)      0.697                              
  Long-term oxygen therapy                                                   Yes                  4     0 (0.0%)     0.97 (0.03, 27.03)     0.985                              
  HCAP/CAP                                                                   HCAP                 29    4 (13.8%)    1.91 (0.52, 7.03)      0.328    4.41 (0.64, 30.30)        0.131
  Performance status                                                         Unknown              16    2 (12.5%)    1.55 (0.30, 8.04)      0.600    0.46 (0.04, 4.72)         0.511
                                                                             PS 3-4               11    1 (9.1%)     1.29 (0.17, 9.46)      0.805    0.12 (0.00, 3.36)         0.212
                                                                             PS 1-2               24    2 (8.3%)     1.00 (0.20, 4.97)      1.000    0.59 (0.07, 4.62)         0.613
                                                                             PS 0                 54    5 (9.3%)     Reference                       Reference                 
  Charlson Comorbidity Index                                                 High, Very high      1     0 (0.0%)     3.15 (0.03, 291.68)    0.620                              
                                                                             Medium               62    6 (9.7%)     0.98 (0.27, 3.55)      0.980                              
                                                                             Low                  42    4 (9.5%)     Reference                                                 
  Bacteremia                                                                 Yes                  3     0 (0.0%)     1.26 (0.04, 40.90)     0.897                              
  Complications                                                                                                                                                                
   Pneumothorax                                                              Yes                  1     1 (100.0%)                                                             
   Pleuritis or pyothorax                                                    Yes                  2     1 (50.0%)    9.94 (0.57, 172.22)    0.114                              
   Acute kidney disease                                                      Yes                                                                                               
   Acute pulmonary thromboembolism                                           Yes                  5     4 (80.0%)    43.62 (4.95, 384.39)   \<.001   20.72 (1.49, 288.51)      0.024
   Acute pulmonary thromboembolism                                           Yes                  0     0 (0.0%)                                                               
   Myocarditis                                                               Yes                  1     0 (0.0%)     2.98 (0.03, 290.36)    0.641                              
   Neurological symptoms (encephalitis, meningitis)                          Yes                  2     1 (50.0%)    9.94 (0.57, 172.22)    0.114                              
   Rhabdomyolysis                                                            Yes                  7     1 (14.3%)    2.17 (0.29, 16.28)     0.450                              
  Severity                                                                   Severe               26    8 (30.8%)    14.24 (3.13, 64.71)    \<.001   8.07 (1.66, 39.22)        0.010
  Concordance with CAP guideline-recommended treatment                       Discordant           38    5 (13.2%)    1.87 (0.53, 6.62)      0.335    1.63 (0.29, 9.20)         0.578
  Number of initial antibiotics                                              ≥2 drugs             66    6 (9.1%)     0.85 (0.23, 3.06)      0.801                              
  Neuraminidase inhibitors                                                   No                   20    2 (10.0%)    0.84 (0.18, 3.99)      0.824                              
                                                                             ≥48 h                32    1 (3.1%)     0.30 (0.05, 1.85)      0.193                              
                                                                             \<48 h               53    7 (13.2%)    Reference                                                 

CAP, community-acquired pneumonia; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; HCAP, healthcare-associated pneumonia; NTM, nontuberculous mycobacteriosis.
